In the year marked by the first modern pandemic of COVID-19, Tchaikapharma provided access to therapy to thousands of Bulgarians suffering from rheumatoid diseases by adding MoriVid (hydroxychloroquine sulfate) to its portfolio. The use of hydroxychloroquine is widely recognized as a successful strategy for prophylaxis and early treatment of COVID-19.